Aurinia Pharmaceuticals AUPH Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's change in accrued liabilities?
- Aurinia Pharmaceuticals (AUPH) reported change in accrued liabilities of -$5.59M in Q1 2026.
- How has Aurinia Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Aurinia Pharmaceuticals's change in accrued liabilities increased by 76.1% year-over-year, from -$23.41M to -$5.59M.
- What is the long-term trend for Aurinia Pharmaceuticals's change in accrued liabilities?
- Over 2 years (2022 to 2024), Aurinia Pharmaceuticals's change in accrued liabilities has grown at a 199.0% compound annual growth rate (CAGR), from $1.49M to $13.33M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.